Veröffentlichungen 2006
Publikationen
1. Askoxylakis V, Mier W, Zitzmann S, Ehemann V, Zhang J, Kramer S, Beck C, Schwab M, Eisenhut M, Haberkorn U. Characterization and Development of a Peptide (p160) with Affinity for Neuroblastoma Cells. J Nucl Med 2006;47(6):981-988.
2. Bartenstein M, Baum RP, Dietlein M, Geworski L, Haberkorn U, Kluge R, Knapp WH, Kotzerke J, Kuwert T, Nitzsche E, Reske SN, Reuland P, Schicha H, Schober O, Schwaiger M, Stabell U, van den Hoff, J. Positronen-Emissions-Tomographie in der Onkologie – Bestandteil der ärztlichen Behandlungskunst. Dtsch Med Wochenschr 2006;131:512-515.
3. Buchmann I, Hansen T, Brochhausen C, Kneist W, Oberholzer K, Junginger T, Schreckenberger M , Bartenstein P. FDG-PET in the Inital Staging of Squamous Cell Esophageal Carcinoma. Nuklearmedizin 2006; 45(6):235-41.
4. Calderon Sanchez O, Mohammed A, Bauer C, Wolf M, Wängler B, Mier W, Haberkorn U, Mocelo R, Eisenhut M. 99mTc Complexes with activated ester functions; ligands comprising a 3,4-diamino-benzoate backbone. Nucl Med Biol 2006;33:381-390.
5. Chen L, Altman A, Mier W, Lu H, Zhu R, Haberkorn U. (99m)Tc-pertechnetate uptake in hepatoma cells due to tissue-specific human sodium iodide symporter gene expression. Nucl Med Biol 2006;33(4):575-580.
6. Chen L, Altmann A, Mier W, Eskerski H, Leotta K, Guo L, Zhu R, Haberkorn U. Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene. J Nucl Med 2006;47:854-862.
7. Dimitrakopoulou-Strauss A, Strauss LG. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planing of oncological patients. Hell J Nucl Med 2006;9(1):10-21.
8. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Mäcke HR, Haberkorn U, Strauss LG. Quantitative assessment of SSTR2 expression in patients with non-small-cell lung cancer using 68Ga-DOTATOC PET and comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2006;33:823-830.
9. Dimitrakopoulou-Strauss A, Wilmsmeyer M, König S, Schubert S, Neff KW, Haberkorn U, Strauss LG. 18F-FDG PET in a 10-years-old female patient with subacute sclerosing panencephalitis. Eur J Nucl Med Mol Imaging 2006;33:1100-1101.
10. Dinter D, Willeke F, Strauss L, Neff KW, Düber C. Staging des Rektumkarzinoms mit CT, MRT und PET. Chir Praxis 2006;66:175-196.
11. Eisenhut M, Haberkorn U. Molecular Position of Radiolabels and Its Impact on Functional Integrity of Proteins. J Nucl Med 2006;47(9):1400-1402.
12. Haufe SE, Riedmuller K, Haberkorn U. Nuclear medicine procedures for the diagnosis of acute and chronic renal failure. Nephron Clin Pract 2006;103(2):c77-84.
13. Henze M, Özdemir-Sahin N, Hipp P, Mier W, Eisenhut M, Debus J, Haberkorn U. Comparison of the diagnostic accuracy of 18F-FDG PET, 123I-IMT- and 99mTc-MIBI SPECT. Evaluation of tumor progression in irradiated low grade astrocytomas. Nuklearmedizin 2006;45:49-56.
14. Hunt A, Schönknecht P, Henze M, Toro P, Haberkorn U, Schröder J. CSF tau protein and FDG PET in patients with aging-associated cognitive decline and Alzheimer’s disease. Neuropsychiatric Disease and Treatment 2006;2(2):207-212.
15. Jensen AD, Munter MW, Bischoff H, Haselmann R, Timke C, Krempien R, Sterzing F, Nill S, Heeger S, Hoess A, Haberkorn U, Huber PE, Steins M, Thomas M, Debus J, Herfarth KK. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518). BMC Cancer 2006: 6:122.
16. Kiessling F, Heilmann M, Lammers T, Ulbrich K, Subr V, Peschke P, Waengler B, Mier W, Schrenk HH, Bock M, Schad L, Semmler W. Synthesis and characterization of HE-24.8: a polymeric contrast agent for magnetic resonance angiography. Bioconjug Chem 2006;17:(1):42-51.
17. Kontaxakis G, Visvikis D, Ohl R, Sachpazidis, I, Suarez JP, Selby P, Cheze-Le Rest C, Santos A, Ortega F, Diaz J, Pan L, Strauss LG, Dimitrakopoulou-Strauss A, Sakas G, Pozo MA. Integrated telemedicine applications and services for oncological positron emission tomography. Oncol Rep 2006;15(4):1091-100.
18. Kontaxakis G, Pozo MA, Ohl R, Visvikis D, Sachpazidis I, Ortega F, Guerra P, Cheze-Le Rest C, Selby P, Pan L, Diaz J, Dimitrakopoulou-Strauss A, Santos A, Strauss LG, Sakas, G. European health telematics networks for positron emission tomography. Nucl Instrum Methods Phys Res Sect A 2006:569(2):626-630.
19. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Evaluation of the pharmacokinetic of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:460-466.
20. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss, A. Comparison of the pharmacokinetics of (68Ga)-DOTATOC and (18F)-FDG in patients with metastatic neuroendocrine tumors scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115-1122.
21. Kunz P, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Eisenhut M, Bonaterra GA, Dengler TJ, Mier W, Haberkorn U, Kinscherf R. Angiopoietin-2-overexpression in Morris hepatoma results in increased tumor perfusion and induction of critical angiogenesis-promoting genes. J Nucl Med 2006;47:1515-1524.
22. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A, Haberkorn U, Debus J. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [(68)Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys 2006;65(1):222-227.
23. Schmidt K, Hoffend J, Altmann A, Strauss LG, Dimitrakopoulou-Strauss A, Engelhardt B, Koczan D, Peter J, Dengler TJ, Mier W, Eisenhut M, Haberkorn U, Kinscherf R. Angiostatin overexpression in Morris hepatoma results in decreased tumor growth but increased perfusion and vascularization. J Nucl Med 2006;47:543-551.
24. Schmidt K, Hoffend J, Altmann A, Kiessling F, Strauss LG, Koczan D, Mier W, Eisenhut M, Kinscherf R, Haberkorn U. Troponin I Overexpression Inhibits Tumor Growth, Perfusion and Vascularization of Morris Hepatoma. J Nucl Med 2006:47:1506-1514.
25. Wängler B, Beck C, Wagner-Utermann U, Schirrmacher E, Bauer C, Rösch F, Schirrmacher R, Eisenhut M. Application of tris-allyl-DOTA in the preparation of DOTA-peptide conjugates. Tetrahedron Letters 2006;47:5985-8.
26. Wolf M, Eskerski H, Bauder-Wust U, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model. Melanoma Res 2006:16(6):487-96.
27. Wolf M, Bauder-Wust U, Pipkorn R, Eskerski H, Eisenhut M. Fluorophor-labeled spermidine derivatives as fluorescent markers in optical tumor imaging. Bioorg Med Chem Lett 2006;16(12):3193-6.
Buchbeiträge
1. Haberkorn U. Le rôle de la biotechnologie dans l’imagerie des tumeurs. In : Boiron M, Marty M (eds .) Eurocancer 2006. John Libbey Eurotext, Surrey 2006; pp 33-34. ISBN 2742006362.
2. Hoffner S, Willeke F, Haberkorn U. Schilddrüsenkarzinom. In: Layer G, van Kaick G, Delorme S (eds.) Radiologische Diagnostik in der Onkologie. Springer-Verlag Berlin Heidelberg 2006; pp 41-64. ISBN 3540669914.
3. Strauss LG, Dimitrakopoulou-Strauss A. Clinical Advances in PET and Tracer Development. In: Padhani AR, Choyke PL (ed.) New techniques in Oncologic imaging. Taylor & Francis, New York, London, 2006; pp 145-166. ISBN 0849392748.